- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Goodbye 2022—The Top 10 Biosimilars Stories of the Year
To say goodbye to 2022 and welcome in the new year, The Center for Biosimilars recaps the biggest news stories and milestones from the past 12 months as well as list of the top 5 podcast episodes of the year.
On this episode, we’re going to review the top stories and milestones to hit the biosimilar industry this year. From the launch of a generic lenalidomide, the FDA approval of a high-concentration adalimumab biosimilar, to the launch of the first ophthalmology biosimilar. We’re also going to be recommending our top 5 podcast episodes of the year so stick around to hear more about what 2022 has in store for biosimilars around the world.
Show notes
Top 10 stories of the year:
10. FDA Approves Stimufend, the US’ Sixth Pegfilgrastim Biosimilar
9. Contributor: No Animal Testing of Biosimilars—US Congress Begins Amendment to BPCIA
8. AbbVie Settles ITC Case With Alvotech; Humira Biosimilar to Launch July 2023
7. Review: Biobetters and Biosimilars Set to Emerge in Ophthalmology
6. Report: Biosimilar Competition in Europe
5. Part 1: Biosimilars to Bring a Bumper Crop of Adalimumab Options
- For the whole series, click here.
4. FDA Accepts BLAs Supporting Interchangeability From Alvotech, Pfizer for Biosimilars to Humira
3. Samsung Bioepis and Organon Seek to Enter the Market for High-Concentration Adalimumab
2. FDA Approves High-Concentration Formulation of Samsung Bioepis’ Humira Biosimilar
1. Teva Announces US Launch of Lenalidomide, Generic of Revlimid
Top 5 podcast episodes of the year:
5. How Health Policy Can Impact Adoption for Adalimumab Biosimilars
3. What Amgen’s Biosimilar Trends Report Says About the Future of Biosimilars
2. How Health Policies May Take Shape in a Post-Humira-Exclusive Adalimumab Market
Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
March 5th 2023On this episode of Not So Different, we chronicle the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
AAM's Craig Burton: Is the Biden Administration Doing Enough to Help Biosimilars?
November 13th 2022Craig Burton, senior vice president of policy and strategic alliances at the Association for Accessible Medicines and executive director of the Biosimilars Council, gives insight into the many health policies that the Biden administration has implemented in 2022 as well as their possible impact on biosimilar adoption.
How Health Policy Can Impact Adoption for Adalimumab Biosimilars
September 25th 2022In this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, discussed current policy initiatives that could help biosimilar adoption and how the Inflation Reduction Act is expected to influence the adalimumab market.
